The role of vitamin D up-regulated protein 1 in epithelial ovarian cancer

Purpose: The objective of this study was to verify the relationship between the expression of VDP1 and Jun activation domain-binding protein 1 (Jab1) and cyclin-dependent kinase inhibitor 1B (CDKN1B: p27kip1) in ovarian cancer cell strains. Materials and Methods: The ovarian cancer cell lines SK-OV-3, OVCAR-3 were plated and cultivated for 24 hours in a 37°C carbon dioxide incubator. Thereafter, vitamin D was added at various concentrations, and the cells were cultivated for an additional 24 hours. Using the 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay, cell growth was checked, and changes in the protein level were observed using Western blotting, immunofluorescence and immunocytochemistry. Results: The authors found that the viability of the ovarian cancer cells was decreased by vitamin D, dose dependently. The results of Western blotting, immunofluorescence, and immunocytochemistry revealed that p27kip1 and VDUP1 increased, while Jab1 decreased, dose dependently. Conclusion: These findings show the relationship between p27kip1, Jab1 and VDUP1 following vitamin D treatment in ovarian cancer, indicating a correlation with cancer cell proliferation.

Epithelial ovarian neoplasms; Jab1; p27kip1; VDUP1 protein; Vitamin D

[1] Bonome T., Lee J.Y., Park D.C., Radonovich M., Pise-Masison C., Brady J., et al.: “Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary”. Cancer Res., 2005, 65, 10602.

[2] Sherman M.E., Mink P.J., Curtis R., Cote TR., Brooks S., Hartge P., et al.: “Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis”. Cancer, 2004, 100, 1045.

[3] Bai W., Oliveros-Saunders B., Wang Q., Acevedo-Duncan M.E., Nicosia S.V.: “Estrogen stimulation of ovarian surface epithelial cell proliferation”. In Vitro Cell Dev Biol Anim., 2000, 36, 657.

[4] Gong T.T., Wu Q.J., Vogtmann E., Lin B., Wang Y.L.: “Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies”. Int. J. Cancer, 2013, 132, 2894.

[5] Tung K.H., Goodman M.T., Wu A.H., McDuffie K., Wilkens L.R., Kolonel L.N., et al.: “Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study”. Am. J. Epidemiol., 2003, 158, 629.

[6] Feldman D.: “Vitamin D, parathyroid hormone, and calcium: a complex regulatory network”. Am J Med., 1999, 107, 637.

[7] Norman A.W.: “Minireview: vitamin D receptor: new assignments for an already busy receptor”. Endocrinology, 2006, 147, 5542.

[8] Chakraborti C.K.: “Vitamin D as a promising anticancer agent”. Indian J. Pharmacol., 2011, 43, 113.

[9] Han S.H., Jeon J.H., Ju H.R., Jung U., Kim K.Y., Yoo H.S., et al.: “VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression”. Oncogene, 2003, 22, 4035.

[10] Junn E., Han S.H., Im J.Y., Yang Y., Cho E.W., Um H.D., et al.: “Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function”. J Immunol., 2000, 164, 6287.

[11] Baker A.F., Dragovich T., Tate W.R., Ramanathan R.K., Roe D., Hsu C.H., et al.: “The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma”. J. Lab. Clin. Med., 2006, 147, 83.

[12] Tomoda K., Kubota Y., Kato J.: “Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1”. Nature, 1999, 398, 160.

[13] Jeon J.H., Lee K.N., Hwang C.Y., Kwon K.S., You K.H., Choi I.: “Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1”. Cancer Res., 2005, 65, 4485.

[14] Siegel R., Ward E., Brawley O., Jemal A. “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths”. CA Cancer J. Clin., 2011, 61, 212.

[15] Modugno F., Laskey R., Smith A.L., Andersen C.L., Haluska P., Oesterreich S.: “Hormone response in ovarian cancer: time to reconsider as a clinical target?” Endocr Relat Cancer., 2012, 19, R255.

[16] Gui T., Shen K.: “The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer”. Cancer Epidemiol., 2012, 36, 490.

[17] Romero I., Bast R.C. Jr.: “Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy”. Endocrinology, 2012, 153, 1593.

[18] Tutt A., Ashworth A.: “The relationship between the roles of BRCA genes in DNA repair and cancer predisposition”. Trends Mol. Med., 2002, 8, 571.

[19] Crijnen T.E., Janssen-Heijnen M.L., Gelderblom H., Morreau J., Nooij M.A., Kenter G.G., et al.: “Survival of patients with ovarian cancer due to a mismatch repair defect”. Fam. Cancer, 2005, 4, 301.

[20] Lancaster J.M., Carney M.E., Futreal P.A. “BRCA 1 and 2—A Ge- netic Link to Familial Breast and Ovarian Cancer”. Medscape Womens Health, 1997, 2, 7.

[21] Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., et al.: “Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial”. JAMA, 2011, 305, 2295.

[22] Smolle E., Taucher V., Pichler M., Petru E., Lax S., Haybaeck J.: “Targeting signaling pathways in epithelial ovarian cancer”. Int. J. Mol. Sci., 2013, 14, 9536.

[23] Trabert B., Ness RB., Lo-Ciganic W.H., Murphy M.A., Goode E.L., Poole E.M., et al.: “Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium”. J. Natl. Cancer Inst., 2014, 106, djt431.

[24] Faivre S., Kroemer G., Raymond E.: “Current development of mTOR inhibitors as anticancer agents”. Nat. Rev. Drug. Discov., 2006, 5, 671.

[25] Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al.: “Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer”. N Engl J Med., 2012, 366, 1382.

[26] Agic A., Xu H., Altgassen C., Noack F., Wolfler M.M., Diedrich K., et al.: “Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers”. Reprod. Sci., 2007, 14, 486.

[27] Toriola A.T., Surcel H.M., Agborsangaya C., Grankvist K., Tuohimaa P., Toniolo P., et al.: “Serum 25-hydroxyvitamin D and the risk of ovarian cancer”. Eur. J. Cancer, 2010, 46, 364.

[28] Dusso A.S., Brown A.J., Slatopolsky E.: “Vitamin D”. Am. J. Physiol. Renal Physiol., 2005, 289, F8.

[29] Chang E.M., Kim Y.S., Won H.J., Yoon T.K., Lee W.S.: “Association between sex steroids, ovarian reserve, and vitamin D levels in healthy nonobese women”. J. Clin. Endocrinol. Metab., 2014, 99, 2526.

[30] Lerchbaum E., Rabe T.: “Vitamin D and female fertility”. Curr. Opin. Obstet. Gynecol., 2014, 26, 145.

[31] Blomberg Jensen M.: “Vitamin D metabolism, sex hormones, and male reproductive function”. Reproduction, 2012, 144, 135.

[32] Jablonski N.G., Chaplin G.: “The evolution of human skin coloration”. J. Hum. Evol., 2000, 39, 57.

[33] Poon A.H., Mahboub B., Hamid Q.: “Vitamin D deficiency and severe asthma”. Pharmacol Ther., 2013, 140, 148.

[34] Deeb K.K., Trump D.L., Johnson C.S.: “Vitamin D signalling pathways in cancer: potential for anticancer therapeutics”. Nat. Rev. Cancer, 2007, 7, 684.

[35] Kim K.Y., Shin S.M., Kim J.K., Paik S.G., Yang Y., Choi I.: “Heat shock factor regulates VDUP1 gene expression”. Biochem. Biophys. Res. Commun., 2004, 315, 369.

[36] Yoshioka J., Schulze P.C., Cupesi M., Sylvan J.D., MacGillivray C., Gannon J., et al.: “Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity”. Circulation, 2004, 109, 2581.

[37] Arner E.S., Holmgren A.: “The thioredoxin system in cancer”. Semin. Cancer Biol., 2006, 16, 420.

[38] Tonissen K.F.: “Targeting the human thioredoxin system by diverse strategies to treat cancer and other pathologies”. Recent. Pat. DNA Gene Seq., 2007, 1, 164.

[39] Wang Y., De Keulenaer G.W., Lee R.T.: “Vitamin D(3)-upregulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin”. J. Biol. Chem., 2002, 277, 26496.

[40] Zhang H., Schneider J., Rosdahl I.: “Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells”. Int. J. Oncol., 2002, 21, 43.

[41] Sherr C.J.: “Principles of tumor suppression”. Cell., 2004, 116, 235.

[42] Slingerland J., Pagano M.: “Regulation of the cdk inhibitor p27 and its deregulation in cancer”. J. Cell. Physiol., 2000, 183, 10.

[43] Lowe S.W., Sherr C.J.: “Tumor suppression by Ink4a-Arf. “progress and puzzles”. Curr. Opin. Genet. Dev., 2003, 13, 77.

[44] Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massague J., Roberts J.M., et al.: “p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest”. Genes Dev., 1994, 8, 9.

[45] Huang Y.C., Chen J.Y., Hung W.C.: “Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3”. Oncogene, 2004, 23, 4856.

[46] Yang E.S., Burnstein K.L.: “Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm”. J. Biol. Chem., 2003, 278, 46862.